Samsung Bioepis’ RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea

Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as SB2 – for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis and plaque psoriasis. This marks the second regulatory approval for Samsung Bioepis in Korea. The MFDS approved in September 2015 Samsung Bioepis’ BRENZYS®, a biosimilar version of Enbrel® (etanercept), also known as SB4.

Samsung Bioepis Receives Positive CHMP Opinion for the First Etanercept Biosimilar in the European Union

Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Benepali® – a biosimilar version of Enbrel® (etanercept), previously known as SB4 – for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque psoriasis. This marks the first time the CHMP has adopted a positive opinion on an etanercept biosimilar.

Monster Announces Pricing of $125 Million Offering of Convertible Senior Notes Due 2019

Monster (NYSE:MWW) today announced the pricing of an offering of $125 million aggregate principal amount of its convertible senior notes due 2019 (the notes) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Act). Concurrently with the pricing of the notes, Monster entered into a capped call transaction with an affiliate of one of the initial purchasers. The sale of the notes is expected to close on October 22, 2014, subject to customary closing conditions.

Southco Expands SAP ECC 6.0 System Globally under Rimini Street Support

SAP SAPPHIRE NOW 2013 Conference Rimini Street, Inc., the leading third-party maintenance and support provider for enterprise software, including SAP AG (NYSE:SAP) software and Oracle Corporations (NASDAQ: ORCL) Siebel, PeopleSoft, JD Edwards, E-Business Suite, Oracle Database and Hyperion software, today announced that Southco, a leading international provider of engineered access hardware, recently completed the initial phase of its strategic SAP global expansion while utilizing Rimini Street for support of its SAP ECC 6.0 system. Like Southco, hundreds of companies around the world are leveraging third-party support from Rimini Street to reduce total support costs by up to 90 percent while continuing to advance the scope, scale and use of its enterprise software to achieve its business objectives. As a result, many Rimini Street clients, including Southco, are able to use their significant savings from third-party support to fund important business and IT improvements that directly affect their ability to better compete in the global marketplace.